Experiencing shortness of breath while bending forward, termed “bendopnea,” could be an indicator of heart failure, according to researchers at the University of Texas Southwestern Medical Center in Dallas in a study published in the Journal of the American College of Cardiology.

The proportion of women who have cardiac arrest while in the hospital to give birth is much higher than previously believed, based on an analysis of 13 years of data published in the April issue of Anesthesiology. The research found that 1 in 12,000 pregnant women hospitalized for delivery experience cardiac arrest. Most women survive, and survival is increasing over time. 

The federal Office of Research Integrity (ORI) ruled that an Illinois cardiologist engaged in misconduct by bullying fellows and asking attending physicians to falsify information in research records.

Looking for an ice-breaker at the upcoming American College of Cardiology (ACC) scientific session? Try bringing up transcatheter aortic valve replacement (TAVR).

The long-standing recommendations to decrease the intake of saturated fat and increase intake of polyunsaturated fatty acids in order to reduce the risk of heart disease may warrant reconsideration, based on a study published online March 18 in Annals of Internal Medicine. The study found little evidence to support this guideline.

An interactive dance project called 4Chambers includes choreography that depicts a cardiac arrest and video about heart attacks. The work, described in Studio 360, was inspired by a conversation with a cardiologist who encourages her patients to dance, which she calls “the perfect activity.”  

AstraZeneca (NYSE: AZN) today announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying BRILINTA(r) (ticagrelor) tablets. Part of PARTHENON, AstraZeneca's largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States (US) from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.

The Cedars-Sinai Heart Institute has set a new standard for U.S. heart transplantation by completing 117 adult heart transplants and two adult heart-lung transplants, for a total of 119 adult heart transplants in a single year. The previous number set in 2005, was 98 adult heart transplants performed in one year.